Fig. 1From: Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trialsFlow diagram of the literature selection process. DMARD(−IR) disease-modifying antirheumatic drug(−inadequate responder), LTE long-term extensionBack to article page